Shared on 31 Oct 25
Fair value Increased 4.08%The analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.
Shared on 17 Oct 25
Analysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.
Shared on 03 Oct 25
Fair value Increased 9.54%The analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.
Shared on 18 Sep 25
Fair value Increased 7.65%Analysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.
Shared on 29 Jul 25
Fair value Increased 5.31%Roivant Sciences’ consensus price target has been raised from $16.14 to $17.00, primarily reflecting growing analyst optimism around upcoming clinical catalysts—especially the pivotal Phase 3 VALOR trial and brepocitinib’s dermatomyositis readout—which are seen as not fully priced into current shares. Analyst Commentary Positive expectations for a successful outcome in the Phase 3 VALOR clinical trial.